CV Therapeutics Inc. Gibts was neues? - 500 Beiträge pro Seite

[waldi21]

Kann mir jemand helfen und was zu CV Therapeutics Inc.
WKN 912268 sagen?Gabs schlechte nachrichten oder warum ist sie so stark gefallen?
Vielleicht ein günstiger Zeitpunkt zum Einstig?

Danke!

[Guru-Schreck]

Tuesday May 8, 7:00 am Eastern Time

Press Release

SOURCE: CV Therapeutics, Inc.

CV Therapeutics Announces CVT-3146 Phase I Clinical Data Support Decision To Move
Into Phase II

BALTIMORE, May 8 /PRNewswire/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - news) today announced at the Deutsche Banc Alex. Brown 2001
Health Care Conference that results from its Phase I clinical trial of CVT-3146 support initiation of Phase II clinical trials. The Phase I trial met the
Company`s previously established primary objective of providing data on safety and tolerability over a broad range of doses administered to healthy
volunteers. CVT-3146 is a selective short acting coronary vasodilator and is being developed for the potential use as an adjunctive pharmacologic
agent in cardiac perfusion imaging studies. CV Therapeutics is jointly developing CVT-3146 with Fujisawa Healthcare, Inc. (FHI).

``We are extremely pleased with the results obtained from our Phase I clinical trial for CVT-3146,`` said Louis G. Lange, M.D., Ph.D., Chairman and
Chief Executive Officer of CV Therapeutics, Inc. ``CVT-3146 was discovered in 1999, entered this Phase I trial in 2000, and is scheduled to initiate
Phase II trials later this year. This progress demonstrates our ability to quickly move products from discovery to development.``

Cardiac perfusion imaging studies are used for the detection and characterization of coronary artery disease by identifying areas of insufficient blood
flow to the heart. During these tests, the heart is subjected to a period of stress to stimulate maximal blood flow. Areas of poor myocardial perfusion
are detected by imaging during stress and compared to images made when patients are at rest. Relatively poor perfusion during stress compared to rest
indicates which areas of the heart may be perfused by narrowed coronary arteries.

To stress the heart sufficiently to perform the test, many patients exercise on a treadmill. However, more than a third of the patients who take the test
are unable to exercise adequately because of medical conditions such as peripheral vascular disease or arthritis. For these patients, a pharmacologic
agent that temporarily increases coronary blood flow is used to mimic the increase in blood flow caused by exercise. In 1997, approximately 5.2 million
cardiac perfusion imaging studies were performed in the U.S., of which 1.8 million were conducted using a pharmacologic agent.

Activation of the A2A adenosine receptor in the heart causes coronary vasodilation and thus increases coronary blood flow. In animal studies,
CVT-3146 has been shown to increase coronary blood flow without reducing peripheral blood pressure.

CVT and FHI are collaborating on the development of CVT-3146 in North America. Leveraging the strengths of both organizations, CVT is
responsible for managing the CVT-3146 clinical development program. FHI is responsible for selling and marketing CVT-3146 in North America. In
the U.S. FHI currently markets Adenoscan® (adenosine), the market leading pharmacologic agent for use as an adjunct in thallium 201 cardiac
perfusion imaging studies.

Fujisawa Healthcare, Inc. headquartered in Deerfield, Illinois, develops, manufactures and markets proprietary pharmaceutical products in the United
States and abroad. Fujisawa Healthcare, Inc., is a subsidiary of Fujisawa Pharmaceutical Co., Ltd., based in Osaka, Japan. Fujisawa Pharmaceutical
Co., Ltd., founded in 1894, is a leading pharmaceutical manufacturer and is actively developing its international operations in North America, Europe and Asia. Additional information on
Fujisawa Healthcare, Inc., and its products can be found on the company`s web site at www.fujisawa.com.

CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization
of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has three compounds in clinical trials. Ranolazine, the first in a new class of compounds known
as partial fatty acid oxidation (pFOX) inhibitors, is in Phase III clinical trials for the potential treatment of chronic angina. CVT-510, an A1 adenosine receptor agonist, is in Phase II
clinical trials for the potential treatment of atrial arrhythmias. CVT-3146, an A2A adenosine receptor agonist, is in Phase I clinical trials for the potential use as an adjunctive
pharmacologic agent in cardiac perfusion imaging studies. For more information, please visit CV Therapeutics` web site at http://www.cvt.com.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to CVT`s ability to develop CVT-3146, and the potential use of
CVT-3146, are forward-looking statements within the meaning of the ``safe harbor`` provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements
are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; the timing of clinical trials; the dependence on collaborative
and licensing agreements; and other risks detailed from time to time in CVT`s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2000. CVT
disclaims any intent or obligation to update these forward-looking statements.